Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines

J&J’s data showed that a second shot of its vaccine boosts protection to 94% against symptomatic moderate-to-severe infection when administered two months after the first dose

Biogen Idec building

Biogen’s ALS drug tofersen misses phase 3 endpoint

Following these results, Biogen will now expand its early access programme for tofersen to enable all eligible SOD1-ALS patients worldwide to receive the drug free of charge

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

Gilead’s Trodelvy set for EU approval in breast cancer

The positive opinion from EMA’s CHMP means Trodelvy could be available as second-line treatment for unresectable or metastatic breast cancer before the end of the year

- PMLiVE

Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era

By Michael Brandreth, Group Vice President of Medscape

Menopause

Breaking the silence: It’s time to talk about the menopause

Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.

Inizio

regeneron headquarters

FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19

In Europe, the EMA will review a Marketing Authorisation Application for the antibody cocktail

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

- PMLiVE

Beyond yoga and smoothies – providing real support for employee well-being

Virtual exercise class, yoga, smoothie-making competition? Walkathon, anyone? It can only be Well-being Week!With World Mental Health Day on Sunday 10th October, this week felt like a great time to...

Nucleus Global

Driving Healthcare Decisions with Natural Language Processing

Dr. Sabita Sankar, VP of Business Development at HUMA.AI, discusses “human-centric AI” and how to automate healthcare through human language, with special focus on the applications for Medical Affairs, Clinical,...

Impetus Digital

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links